152 AttackMS natalizumab for the treatment of people with inflammatory demyeli- nation suggestive of multiple sclerosis

Conclusions AttackMS will be the first trial of HE-DMT in people with a first event of demyelination, in a hyper-acute setting.
Source: Journal of Neurology, Neurosurgery and Psychiatry - Category: Neurosurgery Authors: Tags: Poster presentations Source Type: research